Saliva Estriol Levels in Women with and Without Prenatal Antidepressant Treatment

Suri, Rita; Hellemann, Gerhard; Cohen, Lee S.; Aquino, Ana; Altshuler, Lori L.

doi:10.1016/j.biopsych.2008.04.015

Cited by 16 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown that SSRIs readily cross the placenta (Hendrick et al, 2003), are present in amniotic fluid (Loughhead et al, 2006) and newborns may experience withdrawal like symptoms after birth (Moses-Kolko et al, 2005). Suri and colleagues (2008) noted higher estriol levels in the latter part of pregnancy among women using anti-depressants, and this may indicate increased/accelerated fetal production of estriol precursors. SSRIs can also lower serotonin levels in platelets which, in some studies have shown clinical evidence of compromised coagulation and predisposition to hemorrhage (Looper, 2007).…”

Section: Conclusion and Discussionmentioning

confidence: 93%

Maternal Depressive Symptoms, Depression, and Psychiatric Medication Use in Relation to Risk of Preterm Delivery

Gavin

Holzman

Siefert

et al. 2009

Women's Health Issues

View full text Add to dashboard Cite

Purpose This study examined associations among maternal depression, measured in several ways, psychiatric medication use in pregnancy, and preterm delivery (PTD). Methods Data were from 3,019 women enrolled in the Pregnancy Outcomes and Community Health Study (1998–2004), a prospective study of pregnant women in five Michigan communities. Information on depressive symptoms, history of depression and psychiatric medication use was ascertained through interviews at mid-pregnancy. These variables and other relevant covariates were incorporated into regression models with a binary outcome, i.e., term (≥ 37 weeks’ gestation) as referent and PTD (< 37 weeks’ gestation). A second set of models used a multi-category outcome, i.e., term as referent and PTD further subdivided by gestational weeks and clinical circumstances. Main Findings The odds of overall PTD was increased among women who used psychiatric medication during pregnancy and had either elevated levels of depressive symptoms at mid-pregnancy (adjusted odds ratio [AOR] = 2.0 [95% CI 1.1, 3.6]) or a history of depression prior to pregnancy (AOR= 1.6 [95% CI 1.1, 2.5]). The combination of psychiatric medication use in pregnancy and depression, prior to pregnancy or within pregnancy, was most strongly linked to a medically indicated delivery at < 35 weeks’ gestation (AOR 2.9 and 3.6 respectively). Conclusions There are at least two plausible explanations for these findings. First, psychiatric medication use in pregnancy may pose an excess risk of PTD. Second, medication use may be an indicator of depressive symptom severity, which is a direct or indirect (i.e., alters behavior) contributing factor to PTD.

show abstract

Section: Conclusion and Discussionmentioning

confidence: 93%

Maternal Depressive Symptoms, Depression, and Psychiatric Medication Use in Relation to Risk of Preterm Delivery

Gavin

Holzman

Siefert

et al. 2009

Women's Health Issues

View full text Add to dashboard Cite

show abstract

“…Moreover, the use of SSRIs alters the 5-TH levels increased risk of intrauterine growth retardation and preterm delivery by impairing placental blood flow [15]. It is also reported that women using antidepressants had higher saliva estriol levels compared to non-users [16] and elevated levels of estriol have been associated with preterm birth [17]. Secondly, antidepressant medication are prescribed to treat depression so that the observed associations could be explained by the residual depressive symptoms.…”

Section: Discussionmentioning

confidence: 99%

Is the Risk of Preterm Birth and Low Birth Weight Affected by the Use of Antidepressant Agents during Pregnancy? A Population-Based Investigation

et al. 2016

View full text Add to dashboard Cite

BackgroundUntreated depression during pregnancy increases the risk of morbidity and mortality in the mother and child. Therefore, specific treatments are required for this population.ObjectiveThe study aimed to investigating the effect of antidepressant medication used during pregnancy with reference to the risk of preterm birth (PTB) and low birth weight (LBW).MethodsA population-based study was carried out with data provided by the healthcare utilization database of Lombardy, an Italian region with about ten million inhabitants. The study included 384,673 births from 2005 to 2010. Maternal use of antidepressants before and during pregnancy was investigated. Log-binomial regression was used to estimate the association between the use of antidepressants during pregnancy, compared to the non-use or use just before pregnancy, and the prevalence ratio of PTB and LBW.ResultsWomen who used antidepressants during pregnancy had a 20% (95% CI: 10–40%) increased prevalence of both PTB and LBW compared to those who never used antidepressants. There was no evidence that women who used antidepressants during pregnancy had a higher prevalence of the considered outcomes compared to women who used antidepressants before pregnancy, but stopped during pregnancy. Such findings were confirmed by considering separately the effects of SSRIs and other antidepressants together.ConclusionsOur findings suggest that depression in itself, rather than antidepressant medication, might be implicated in the causal pathway of PTB and LBW.

show abstract

“…These efforts encompassed gene expression profiling of peripheral mononuclear cells (1, 2), biochemical evaluations of serum (3), urine (4), saliva (5), and cerebrospinal fluid (6), gene association studies of DNA markers (7) and many other approaches. More recently, inducible pluripotent stem cells (IPSCs) emerged as a very promising model for studying neuronal lineage disturbances across various disorders (8–10).…”

Section: Introductionmentioning

confidence: 99%

Coordinated Messenger RNA/MicroRNA Changes in Fibroblasts of Patients with Major Depression

Garbett

Vereczkei

Kálmán

et al. 2015

Biological Psychiatry

View full text Add to dashboard Cite

Background Peripheral biomarkers for major psychiatric disorders have been an elusive target for the last half a century. Dermal fibroblasts are a simple, relevant, and much underutilized model for studying molecular processes of patients with affective disorders as they share considerable similarity of signal transduction with neuronal tissue. Methods Cultured dermal fibroblast samples from patients with Major Depressive Disorder (MDD) and matched controls (CNTR) (n=16 pairs, 32 samples) were assayed for genome wide mRNA expression using microarrays. In addition, a simultaneous qPCR-based assessment of >1,000 miRNA species was performed. Finally, to test the relationship between the mRNA-miRNA expression changes, the two datasets were correlated with each other. Results Our data revealed that MDD fibroblasts, when compared to matched controls, showed a strong mRNA gene expression pattern change in multiple molecular pathways, including cell-to-cell communication, innate/adaptive immunity and cell proliferation. Furthermore, the same patient fibroblasts showed altered expression of a distinct panel of 38 miRNAs, which putatively targeted many of the differentially expressed mRNAs. The miRNA-mRNA expression changes appeared to be functionally connected, as the majority of the miRNA and mRNA changes were in the opposite direction. Conclusions Our data suggest that a combined miRNA-mRNA assessments are informative about the disease process, and that analyses of dermal fibroblasts might lead to the discovery of promising peripheral biomarkers of MDD, which could be potentially used to aid the diagnosis and allow mechanistic testing of disturbed molecular pathways.

show abstract

Saliva Estriol Levels in Women with and Without Prenatal Antidepressant Treatment

Cited by 16 publications

References 33 publications

Maternal Depressive Symptoms, Depression, and Psychiatric Medication Use in Relation to Risk of Preterm Delivery

Maternal Depressive Symptoms, Depression, and Psychiatric Medication Use in Relation to Risk of Preterm Delivery

Is the Risk of Preterm Birth and Low Birth Weight Affected by the Use of Antidepressant Agents during Pregnancy? A Population-Based Investigation

Coordinated Messenger RNA/MicroRNA Changes in Fibroblasts of Patients with Major Depression

Contact Info

Product

Resources

About